311 related articles for article (PubMed ID: 15390046)
21. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: their relationship to clinical manifestations, mood and cognition.
Triantafyllou NI; Nikolaou C; Boufidou F; Angelopoulos E; Rentzos M; Kararizou E; Evangelopoulos ME; Vassilopoulos D
Parkinsonism Relat Disord; 2008; 14(4):321-5. PubMed ID: 18055246
[TBL] [Abstract][Full Text] [Related]
22. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Müller T; Woitalla D; Muhlack S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
[TBL] [Abstract][Full Text] [Related]
24. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
Hu XW; Qin SM; Li D; Hu LF; Liu CF
Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
[TBL] [Abstract][Full Text] [Related]
25. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
Gorgone G; Currò M; Ferlazzo N; Parisi G; Parnetti L; Belcastro V; Tambasco N; Rossi A; Pisani F; Calabresi P; Ientile R; Caccamo D
Neuromolecular Med; 2012 Mar; 14(1):84-90. PubMed ID: 22354693
[TBL] [Abstract][Full Text] [Related]
26. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
[TBL] [Abstract][Full Text] [Related]
27. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
[No Abstract] [Full Text] [Related]
28. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Müller T; Kuhn W
Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD).
Song IU; Kim JS; Park IS; Kim YD; Cho HJ; Chung SW; Lee KS
Arch Gerontol Geriatr; 2013; 57(3):288-91. PubMed ID: 23706974
[TBL] [Abstract][Full Text] [Related]
30. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
31. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.
Siniscalchi A; Gallelli L; Mercuri NB; Ibbadu GF; De Sarro G
Nutr Neurosci; 2006; 9(1-2):11-6. PubMed ID: 16910165
[TBL] [Abstract][Full Text] [Related]
32. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
33. Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis.
Xie Y; Feng H; Peng S; Xiao J; Zhang J
Neurosci Lett; 2017 Jan; 636():190-195. PubMed ID: 27840145
[TBL] [Abstract][Full Text] [Related]
34. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
35. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
[TBL] [Abstract][Full Text] [Related]
36. [Homocysteine and cognitive impairment in Parkinson's disease].
Martín-Fernández JJ; Carles-Díes R; Cañizares F; Parra S; Avilés F; Villegas I; Morsi-Hassan O; Fernández-Barreiro A; Herrero MT
Rev Neurol; 2010 Feb 1-15; 50(3):145-51. PubMed ID: 20146187
[TBL] [Abstract][Full Text] [Related]
37. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Nissinen E; Nissinen H; Larjonmaa H; Väänänen A; Helkamaa T; Reenilä I; Rauhala P
J Neural Transm (Vienna); 2005 Sep; 112(9):1213-21. PubMed ID: 15614425
[TBL] [Abstract][Full Text] [Related]
38. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations.
Ozer F; Meral H; Hanoglu L; Aydemir T; Yilsen M; Cetin S; Ozturk O; Seval H; Koldas M
Neurol Res; 2006 Dec; 28(8):853-8. PubMed ID: 17288745
[TBL] [Abstract][Full Text] [Related]
39. Plasma homocysteine, folate and vitamin B12 levels in Parkinson's disease in China: A meta-analysis.
Dong B; Wu R
Clin Neurol Neurosurg; 2020 Jan; 188():105587. PubMed ID: 31733593
[TBL] [Abstract][Full Text] [Related]
40. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
